HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

The flavoprotein FOXRED2 reductively activates nitro-chloromethylbenzindolines and other hypoxia-targeting prodrugs.

Abstract
The nitro-chloromethylbenzindoline prodrug SN29428 has been rationally designed to target tumour hypoxia. SN29428 is metabolised to a DNA minor groove alkylator via oxygen-sensitive reductive activation initiated by unknown one-electron reductases. The present study sought to identify reductases capable of activating SN29428 in tumours. Expression of candidate reductases in cell lines was modulated using forced expression and, for P450 (cytochrome) oxidoreductase (POR), by zinc finger nuclease-mediated gene knockout. Affymetrix microarray mRNA expression of flavoreductases was correlated with SN29428 activation in a panel of 23 cancer cell lines. Reductive activation and cytotoxicity of prodrugs were measured using mass spectrometry and antiproliferative assays, respectively. SN29428 activation under hypoxia was strongly attenuated by the pan-flavoprotein inhibitor diphenyliodonium, but less so by knockout of POR suggesting other flavoreductases contribute. Forced expression of 5-methyltetrahydrofolate-homocysteine methyltransferase reductase (MTRR), as well as POR, increased activation of SN29428 in hypoxic HCT 116 cells. SN29428 activation strongly correlated with expression of POR and also FAD-dependent oxidoreductase domain containing 2 (FOXRED2), in cancer cell lines. This association persisted after removing the effect of POR enzyme activity using first-order partial correlation. Forced expression of FOXRED2 increased SN29428 activation and cytotoxicity in hypoxic HEK293 cells and also increased activation of hypoxia-targeted prodrugs PR-104A, tirapazamine and SN30000, and increased cytotoxicity of the clinical-stage prodrug TH-302. Thus this study has identified three flavoreductases capable of enzymatically activating SN29428, one of which (FOXRED2) has not previously been implicated in xenobiotic metabolism. These results will inform future development of biomarkers predictive of SN29428 sensitivity.
AuthorsFrancis W Hunter, Jagdish K Jaiswal, Daniel G Hurley, H D Sarath Liyanage, Sarah P McManaway, Yongchuan Gu, Susan Richter, Jingli Wang, Moana Tercel, Cristin G Print, William R Wilson, Frederik B Pruijn
JournalBiochemical pharmacology (Biochem Pharmacol) Vol. 89 Issue 2 Pg. 224-35 (May 15 2014) ISSN: 1873-2968 [Electronic] England
PMID24632291 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2014 Elsevier Inc. All rights reserved.
Chemical References
  • CEN-209
  • Cyclic N-Oxides
  • Flavoproteins
  • Indoles
  • Prodrugs
  • Triazines
  • Foxred2 protein, rat
  • Oxidoreductases
Topics
  • Cell Hypoxia (drug effects, physiology)
  • Cyclic N-Oxides (chemistry, pharmacology)
  • Flavoproteins (biosynthesis)
  • HCT116 Cells
  • HEK293 Cells
  • Hep G2 Cells
  • Humans
  • Indoles (administration & dosage, chemistry, metabolism)
  • Oxidation-Reduction
  • Oxidoreductases (biosynthesis, metabolism)
  • Prodrugs (administration & dosage, chemistry, metabolism)
  • Triazines (chemistry, pharmacology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: